BMS-274
A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab versus Placebo in Subjects with High-Risk Invasive Urothelial Carcinoma (CA209-274).
More Information
NILE
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)
More Information
SGN-22E
A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer (EV-103)
More Information
SWOG-1600
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
More Information